This approval officially makes HER2 low-expression breast cancer a new breast cancer classification, thus allowing more patients to benefit from HER2-targeted therapy, especially those with what would otherwise be considered triple-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.